Skip Navigation



Annals of Oncology Advance Access published online on July 15, 2009
Annals of Oncology, doi:10.1093/annonc/mdp269
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moehler, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moehler, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

M. Moehler1,*, S. Kanzler1, M. Geissler2, J. Raedle3, M. P. Ebert4, S. Daum5, D. Flieger6, T. Seufferlein7, P. R. Galle1, T. Hoehler8 and for the Arbeitsgemeinschaft Internistische Onkologie, Germany

1 Department of Medicine, University of Mainz, Mainz
2 Department of Medicine, University of Freiburg, Freiburg
3 Department of Medicine, Saarland University, Homburg
4 Department of Medicine, Klinikum rechts der Isar, München
5 Department of Medicine, Charité Campus Benjamin Franklin, Berlin
6 Department of Medicine, Klinikum Aschaffenburg, Aschaffenburg
7 Department of Medicine, University Hospital Ulm, Ulm
8 Department of Medicine, Prosper-Hospital Recklinghausen, Recklinghausen, Germany

* Correspondence to: Prof. M. Moehler, Medical Department, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55101 Mainz, Germany. Tel: +49-0-6131-177276; Fax: +49-0-6131-176410; E-mail: moehler{at}mail.uni-mainz.de

Background: The combination of irinotecan with 5-fluorouracil demonstrates efficacy with tolerable safety in the first-line treatment of metastatic gastroesophageal cancer (mGC). This randomized phase II trial compared for the first time capecitabine with irinotecan or cisplatin in this setting.

Patients and methods: Patients were randomly assigned to receive 3-week cycles of capecitabine 1000 mg/m2, twice daily for 14 days, with on day 1 either irinotecan 250 mg/m2 (XI) or cisplatin 80 mg/m2 (XP). The primary end point was overall response rate (ORR) and secondary end points included progression-free survival (PFS), overall survival (OS) and safety.

Results: Of 118 patients recruited, 112 were eligible for safety analysis and 103 for efficacy analysis. In the XI and XP treatment arms, there were no marked differences in ORR, 37.7% versus 42.0%, and median PFS, 4.2 versus 4.8 months, although median OS was longer, 10.2 versus 7.9 months, respectively. Grade 3/4 toxicity was higher in the XP regimen for thrombocytes (18.2% versus 1.8%), nausea (23.6% versus12.3%) and vomiting (16.4% versus 1.8%) and in the XI arm for diarrhea (22.8% versus 7.3%).

Conclusion: The comparable activity and safety of the XI and XP regimens establish XI as a relevant platinum-free first-line treatment choice for patients with mGC.

capecitabine, cisplatin, elderly patients, gastric cancer, irinotecan

Received for publication March 26, 2009. Revision received April 7, 2009. Accepted for publication April 9, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.